| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Research Abstract |
We evaluated the fecal expression of miR-19a, miR-20a, miR-21, miR-92a and miR-106a for 138 patients with colorectal cancer (CRC), 26 patients with advanced adenoma (AA) and 126 control subjects, and compared fecal miRNA assay with a single FIT on same stool samples. Fecal miR-19a, miR-20a, miR-21, miR-92a and miR-106a expressions were significantly higher in CRC and AA than in control. The overall sensitivity of the multi-panel of fecal miRNAs was lower than that of FIT in CRC (60.9% vs. 66.7%, P=0.32). However among subjects with AA, stage 0 and stage I, the sensitivity of the multi-panel of fecal miRNAs was significantly higher than that of FIT (51.4% vs.33.3%, P=0.03). Fecal multi-markers miRNA panel may be useful for screening of colorectal early tumors.
|
